ライフサイエンスコーパス: somatostatin

1 any neuroprotective effect of brimonidine or somatostatin.

2 cell genes including ghrelin, glucagon, and somatostatin.

3 ily to an increase in cells co-positive with somatostatin.

4 jecting CeA neurons express the neuropeptide somatostatin.

5 zation with glucagon but not with insulin or somatostatin.

6 ssion of crucial delta cell genes, including somatostatin.

7 n through a genetic approach by knocking out somatostatin 1.1 (sst1.1) in zebrafish.

8 performed larger tail bends, indicating that Somatostatin 1.1 inhibits spontaneous locomotion.

9 Altogether our study demonstrates that Somatostatin 1.1 innately contributes to slowing down sp

10 Twenty-nine patients (18 receiving somatostatin, 11 placebo) were included in the final ana

11 : 500 mug), followed by a 2.5 mL/h infusion (somatostatin: 250 mug/h) for 5 days.

12 administered intraoperatively as 5-mL bolus (somatostatin: 500 mug), followed by a 2.5 mL/h infusion

13 fusion, HVPG was lower in patients receiving somatostatin (-81.7% vs -58.8%; P = 0.0084), whereas no

14 fts were associated with increased levels of somatostatin, a GH inhibitor, whereas the deleterious ef

15 Baclofen and somatostatin, agonists of Gi-coupled receptors, inhibite

16 ver, the recent approval of the radiolabeled somatostatin analog (177)Lu-DOTATATE has had a significa

17 ne modulation by measuring the effect of the somatostatin analog octreotide on appetitive behavior am

18 four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, te

19 r, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment loca

20 ported for other polypeptide tracers such as somatostatin analogs (2.1-2.6 mSv/100 MBq) and are benef

21 received PRRT with (177)Lu- or (90)Y-labeled somatostatin analogs (DOTATATE or DOTATOC).

22 Somatostatin analogs (SSAs) are recommended for the firs

23 docrine tumors (NETs) are often treated with somatostatin analogs (SSAs) for control of symptoms and

24 PET/CT with (68)Ga-DOTA-somatostatin analogs has been tested for therapy monitor

25 Synthetic somatostatin analogs have been posed as a potential sour

26 onuclide therapy (PRRT) with (177)Lu-labeled somatostatin analogs in patients with somatostatin recep

27 PET/CT using (68)Ga-labeled somatostatin analogs is superior to earlier agents, but

28 endocrine neoplasms by using (177)Lu-labeled somatostatin analogs or in the treatment of advanced pro

29 DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostatin analogs used for the diagnosis of somatosta

30 hese modalities through the radiolabeling of somatostatin analogs with various radionuclides has led

31 nity to treat the patient with radiolabelled somatostatin analogs, which successfully controlled the

32 ptor radionuclide therapy using radiolabeled somatostatin analogs.

33 Therefore, coating CTX with a somatostatin analogue such as octreotide (OCT) is benefi

34 ve had disease progression during first-line somatostatin analogue therapy have limited therapeutic o

35 origin, WHO performance status, and previous somatostatin analogue treatment.

36 antitumour efficacy of the combination of a somatostatin analogue with everolimus in lung and thymic

37 the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended.

38 ctive for late dumping syndrome symptoms and somatostatin analogues are preferred for patients who do

39 ce and previous reports on VHL-HB avidity to somatostatin analogues suggested somatostatin receptor (

40 Medical therapy with somatostatin analogues, cabergoline, and pegvisomant is

41 m evidence for the volume-reducing effect of somatostatin analogues.

42 male participants to a pancreatic clamp with somatostatin and evaluated hepatic glucose and amino aci

43 xpression of other islet hormones, including somatostatin and glucagon.

44 ramidal cells, while concurrently activating somatostatin and inhibiting parvalbumin interneurons.

45 Cortical distributions of somatostatin and parvalbumin cell gene markers are stron

46 Furthermore, while endogenous activity of somatostatin and parvalbumin neurons was strongly biased

47 onstrate stereotyped negative correlation of somatostatin and parvalbumin transcripts within human an

48 both oligodendrocytes and CINs that express somatostatin and parvalbumin.

49 distinct mono-hormonal insulin+, glucagon+, somatostatin+ and PP+ cells and glucose-responsive synch

50 hway, consisting of inhibition by dynorphin, somatostatin, and corticotropin-releasing hormone-expres

51 However, pancreatic polypeptide, somatostatin, and ghrelin cells also contributed to the

52 on of paracrine factors, such as insulin and somatostatin, and juxtacrine signals between EphA4/7 on

53 rum inhibitory cells containing parvalbumin, somatostatin, and neuropeptide Y also show unique topogr

54 parvalbumin, calretinin, neuropeptide Y, and somatostatin, and the number of interneurons were assess

55 These CeA GABA neurons express dynorphin, somatostatin, and/or corticotropin releasing hormone.

56 are associated with changes in parvalbumin-, somatostatin- and neuropeptide Y-positive interneurons.

57 pacity up to the progenitor stage, but favor somatostatin- and pancreatic polypeptide-positive cells

58 calcium imaging, we recorded hippocampal CA1 somatostatin- and parvalbumin-expressing interneurons as

59 ) expression disperse and differentiate into somatostatin- and parvalbumin-expressing interneurons up

60 This study establishes the efficacy of somatostatin as a liver inflow modulator.

61 Ten patients responded to somatostatin bolus, with a significant decrease in hepat

62 ampal inhibitory neurons (those that express somatostatin, but not parvalbumin).

63 ssion of IPSCs from dendritically projecting somatostatin cells (SOM-IPSCs).

64 f two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfu

65 tion, which was associated with the relative somatostatin/dopamine-receptors levels, especially sst5

66 rior anatomical experiments in BLA implicate somatostatin expressing (Sst(+)) INs.

67 hat inhibitory synapses from parvalbumin and somatostatin expressing interneurons undergo long-term d

68 ation of p-eIF2alpha in either excitatory or somatostatin-expressing (but not parvalbumin-expressing)

69 the cortex, parvalbumin-expressing (PV+) and somatostatin-expressing (SOM(+)) interneurons, in mice o

70 neurons, and toward non-CRF(+) (CRF(-)) and somatostatin-expressing (SOM(+)) neurons, while fear ext

71 V1 processes head movements is controlled by somatostatin-expressing (SOM) inhibitory neurons, which

72 e, that causal disruption of either PV(+) or somatostatin-expressing (SST(+)) interneuron activity im

73 vement of parvalbumin-expressing (PV(+)) and somatostatin-expressing (SST(+)) interneurons in gamma o

74 nts and reduced firing of dendrite-targeting somatostatin-expressing (SST) GABAergic interneurons.

75 of pyramidal neurons through suppression of somatostatin-expressing (SST) interneurons and, reciproc

76 In particular, somatostatin-expressing (SST) interneurons selectively i

77 ncy, followed by activation of E neurons and somatostatin-expressing (SST) interneurons.

78 Here we show that, in male rats, 65% of somatostatin-expressing (SST) NTS neurons also express G

79 Somatostatin-expressing (SST+) cells form the second lar

80 We found that activity in most somatostatin-expressing and parvalbumin-expressing inter

81 parvalbumin-expressing CA1 interneurons and somatostatin-expressing CA3 interneurons represented spe

82 ns were distributed across cell layers, with somatostatin-expressing cells predominantly in stratum o

83 Pharmacogenetic activation of somatostatin-expressing cells reduced pyramidal neuron h

84 By contrast, somatostatin-expressing cells-which reside along the sur

85 ic animals that express Pax4 specifically in somatostatin-expressing cells.

86 le of accessing and manipulating a subset of somatostatin-expressing cortical interneurons with high

87 excitatory PNs compared to parvalbumin- and somatostatin-expressing inhibitory INs.

88 Whereas somatostatin-expressing inhibitory neurons are driven by

89 We show that de novo translation in somatostatin-expressing inhibitory neurons in the centro

90 In contrast, somatostatin-expressing inhibitory neurons received very

91 via autonomous mechanisms in excitatory and somatostatin-expressing inhibitory neurons.

92 In sharp contrast, layer 5 PNs and somatostatin-expressing INs were gradually and asynchron

93 asynchronous recruitment of layer 5 PNs and somatostatin-expressing INs.

94 In contrast, somatostatin-expressing interneuronal activity peaks sig

95 sed transgenic mouse line in which GABAergic somatostatin-expressing interneurons (SOM(pos) INs) are

96 whole-cell recordings demonstrated that DLS somatostatin-expressing interneurons (SST-INs) receive d

97 iles of pyramidal cells and parvalbumin- and somatostatin-expressing interneurons during epileptiform

98 uppression across the population, individual somatostatin-expressing interneurons showed consistent l

99 Here, we provide evidence that, in CA1 somatostatin-expressing interneurons, the alpha5-GABA(A)

100 not known what role, if any, is provided by somatostatin-expressing interneurons, which target the d

101 retinin-positive terminals onto dendrites of somatostatin-expressing interneurons.

102 intense activation of both parvalbumin- and somatostatin-expressing interneurons.

103 t mechanisms from parvalbumin-expressing and somatostatin-expressing interneurons.

104 se of 148 MBq (4.0 mCi) for the detection of somatostatin-expressing NETs.

105 We also identified somatostatin-expressing neurons in the preBotC and PHOX2

106 e further characterize a novel population of somatostatin-expressing neurons through anatomical and b

107 mediated by GH-releasing hormone (GHRH)- or somatostatin-expressing neurons.

108 ly one-third of putative dendrite-targeting (somatostatin-expressing) interneurons, but only a neglig

109 r translocation and repositioning within the somatostatin gene promoter.

110 Somatostatin, ghrelin, and GH-releasing hormones that re

111 ptor or dopamine D(2) receptor was seen with somatostatin, glucagon, or polypeptide Y.

112 ut remained unchanged in the brimonidine and somatostatin groups.

113 For example, somatostatin has been previously shown to induce locomot

114 The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Prima

115 Here, we investigated the role of somatostatin in innate locomotion through a genetic appr

116 ition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma in

117 Somatostatin infusion counteracted the decrease in arter

118 Somatostatin infusion during LT in patients with CSPH is

119 us motif for maintaining this balance is the somatostatin interneuron (SOM-IN) feedback microcircuit.

120 h SATB1, a transcription factor critical for somatostatin interneuron development, and promoted SATB1

121 s, necessitating high-frequency activity for somatostatin interneuron recruitment.

122 In vivo opto-activation of cortical somatostatin interneurons alleviates motor symptoms in a

123 len Human Brain Atlas expression data reveal somatostatin interneurons and astrocytes to be consisten

124 Somatostatin interneurons are likely important to this s

125 hus, layer-specific synaptic properties onto somatostatin interneurons are mediated by both constitut

126 or gain) in models with features typical for somatostatin interneurons but decreased gain in models w

127 duced by DBS or by a stimulation of cortical somatostatin interneurons can restore information proces

128 Therefore, mTORC1 activity in somatostatin interneurons contributes to learning-induce

129 ice), immunohistochemistry revealed that BLA somatostatin interneurons express Y(2)Rs, as do a signif

130 arked deficits in distinct subpopulations of somatostatin interneurons from early postnatal stages of

131 itory input drive from low-threshold-spiking somatostatin interneurons in adulthood, suggesting a cir

132 itutive suppression delays the activation of somatostatin interneurons in circuits, necessitating hig

133 ults demonstrate that activation of cortical somatostatin interneurons may constitute a less invasive

134 cence, consistent with presynaptic Y(2)Rs on somatostatin interneurons mediating the above effects.

135 Since parvalbumin and somatostatin interneurons preferentially target perisoma

136 duced persistent LTP at excitatory inputs of somatostatin interneurons that depends on type I metabot

137 alpha5 subunit (concentrated on hippocampal somatostatin interneurons).

138 Here, we show that mTORC1 activity in somatostatin interneurons, a major subclass of GABAergic

139 ipal neurons, probably from Y(2)R-expressing somatostatin interneurons, some of which coexpress NPY.

140 essing action potential dynamics typical for somatostatin interneurons.

141 ausing increased survival of parvalbumin and somatostatin interneurons.

142 4 is a key regulator of the specification of somatostatin interneurons.

143 ter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR

144 receptor radiotherapy using (177)Lu-labeled somatostatin ligand analogs is a well-established treatm

145 patients allocated to brimonidine (n = 152), somatostatin (n = 145), or placebo (n = 152).

146 anocortin (POMC) subtypes, and an orexigenic somatostatin neuron population.

147 hat the cortex, via cortico-lateral-amygdala somatostatin neurons (CLA-SOM), has a direct inhibitory

148 cognition, and mood-related behaviors, with somatostatin neurons contributing evenly to both behavio

149 and signaling pathways, notably in PYCs and somatostatin neurons, further contribute to behavioral c

150 arily controlled by GH-releasing hormone and somatostatin neurons.

151 PH were randomized double-blindly to receive somatostatin or placebo (2:1).

152 Somatostatin or VIP neuron activation also impaired or e

153 omly assigned to one of three arms: placebo, somatostatin, or brimonidine.

154 amidal neurons by optogenetically activating somatostatin- or parvalbumin-positive interneurons, even

155 three subclasses: parvalbumin positive (PV), somatostatin positive (SOM) and serotonin positive neuro

156 ses of interneurons, the parvalbumin and the somatostatin positive cells, tightly control both up-to-

157 We found that TMEM16B is expressed in somatostatin-positive (SOM(+)) GABAergic neurons of the

158 ll excitatory neurons were pyramidal and all somatostatin-positive (SOM(+)) non-fast-spiking interneu

159 urons was not shared with dendrite-targeting somatostatin-positive (SOM+) interneurons.

160 We focused on somatostatin-positive (SST(+)) GABAergic interneurons be

161 Somatostatin-positive (SST(+)) interneurons expressed th

162 , specifically parvalbumin-positive (PV) and somatostatin-positive (SST) inhibitory interneurons.

163 Furthermore, we observed early deficits of somatostatin-positive and Reelin-positive interneurons i

164 tion of engram-forming cells is regulated by somatostatin-positive dendrite-targeting interneurons, w

165 ll stimulation compared with parvalbumin- or somatostatin-positive interneuron stimulation.

166 h parvalbumin-positive interneurons (PV) and somatostatin-positive interneurons (SOM) to pyramidal ne

167 arvalbumin-positive interneurons (PVINs) and somatostatin-positive interneurons (SSTINs) in male prea

168 In our model, stimulus-tuned somatostatin-positive interneurons develop strong connec

169 had a decreased density of parvalbumin- and somatostatin-positive interneurons in dentate gyrus, but

170 se nucleus incertus (NI) selectively inhibit somatostatin-positive interneurons in the hippocampus, b

171 The recruitment of somatostatin-positive interneurons is likely fundamental

172 nhibitory synapses formed by parvalbumin- or somatostatin-positive interneurons on pyramidal layer 5

173 rincipal cells as well as of parvalbumin- or somatostatin-positive interneurons to study the effects

174 thmic input to the lateral hypothalamus from somatostatin-positive lateral septum cells evokes food a

175 dendritic synaptic inhibitory loop formed by somatostatin-positive Martinotti cells (MCs) and pyramid

176 s and increased activity of central amygdala somatostatin-positive neurons, putatively projecting to

177 lucagon-producing pancreatic alpha-cells and somatostatin-producing delta-cells become insulin-expres

178 NET patients received somatostatin radiopeptide therapy with (90)Y-DOTATOC or

179 dionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approac

180 have shown enhanced tumor targeting by novel somatostatin receptor (SSTR) antagonists compared with c

181 ion of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists.

182 avidity to somatostatin analogues suggested somatostatin receptor (SSTR) expression in VHL-HBs, offe

183 docrine neoplasms (NENs) have long relied on somatostatin receptor (SSTR) expression.

184 Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses t

185 Somatostatin receptor (sstr) scintigraphy for imaging an

186 fficacy, and safety of PRRT in patients with somatostatin receptor (SSTR)-expressing G3 NENs.

187 r available imaging agents for patients with somatostatin receptor (SSTR)-positive neuroendocrine tum

188 Somatostatin receptor (SSTR)-targeted peptide receptor r

189 ronal protein gene product 9.5 [PGP9.5], and somatostatin receptor 1 [SSTR1]).

190 Somatostatin receptor 2 (SSTR2) is frequently overexpres

191 bles detection of meningioma tissue based on somatostatin receptor 2 expression.

192 led octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors

193 for clinical assessment in the treatment of somatostatin receptor 2-expressing neuroendocrine tumors

194 oval of ubiquitin acceptor residues from the somatostatin receptor 3 (SSTR3) and from the orphan GPCR

195 a TGR5 antagonist alone or concurrently with somatostatin receptor agonists represents a potential th

196 a combination of SBI-115 and pasireotide, a somatostatin receptor analogue.

197 varying glomerular filtration rates, kidney somatostatin receptor densities, tumor volumes, and rele

198 Hence, TBR reflects somatostatin receptor density more accurately than SUV a

199 Imaging of somatostatin receptor expression is an established techn

200 UV) in tumors were suggested as a measure of somatostatin receptor expression.

201 s (27 men) with advanced tumors and enhanced somatostatin receptor expression.

202 flux rate (K(i)), as a representation of the somatostatin receptor expression.

203 umors have been suggested to be a measure of somatostatin receptor expression.

204 In this study, we selected the somatostatin receptor imaging agent DOTATOC as the found

205 Somatostatin receptor imaging is a valuable tool in the

206 been posed as a potential source of error in somatostatin receptor imaging through interference with

207 d theoretically lead to misinterpretation of somatostatin receptor imaging with (68)Ga-DOTATATE PET/C

208 found on simultaneous CT or later MR, CT, or somatostatin receptor imaging.

209 r sensory cilia, inhibited enrichment of the somatostatin receptor in primary cilia.

210 e inhibitors to block desensitization of the somatostatin receptor in slices from morphine-treated an

211 Octreotide, a somatostatin receptor ligand that targets somatotroph ad

212 Pharmacological treatments include somatostatin receptor ligands (such as octreotide, lanre

213 Somatostatin receptor PET imaging has had a profound eff

214 brain, preferably with MR, together with the somatostatin receptor scintigraphy (SRS), in each clinic

215 The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cance

216 pads for autocrine activation of a GPCR (the somatostatin receptor SSTR5) with its peptide agonist SR

217 is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are b

218 his concept to a G protein-coupled receptor, somatostatin receptor subtype 2 (SSTR2), in pituitary ce

219 ed with Cu and (64)Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 c

220 ncreased for cells expressing high levels of somatostatin receptor subtype 2.

221 ium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET trace

222 Somatostatin receptor type 2 (SSTR2) expression and (68)

223 of the potassium conductance induced by the somatostatin receptor was also blocked by compound 101 i

224 important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrin

225 maging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors.

226 matostatin analogs used for the diagnosis of somatostatin receptor-expressing neuroendocrine tumors (

227 u-DOTATATE is a most effective treatment for somatostatin receptor-expressing neuroendocrine tumors.

228 abeled somatostatin analogs in patients with somatostatin receptor-expressing tumors is often perform

229 E and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting tran

230 Mice bearing CA20948 somatostatin receptor-positive tumor xenografts were tre

231 eatment approach in inoperable or metastatic somatostatin receptor-positive tumors.

232 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has been used cli

233 ly, offers the possibility of using a single somatostatin receptor-targeted peptide conjugate as a th

234 95% confidence interval (CI) 1.52-4.77] and somatostatin-receptor imaging (OR 3.681, 95% CI 1.809-7.

235 cPanNENs is increased by the use of EUS and somatostatin-receptor imaging and is higher in specializ

236 rodihydroxyphenylalanine (FDOPA), and (68)Ga somatostatin-receptor ligands in NETs has been expanding

237 Overexpression of somatostatin receptors (SSTRs) in patients with neuroend

238 orectal cancer, which is reported to express somatostatin receptors (SSTRs).

239 Targeting dopamine and somatostatin receptors on corticotroph adenomas with cab

240 The high expression of somatostatin receptors on this neuroendocrine neoplasm o

241 ctable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor

242 ses were observed among distinct subtypes of somatostatin+/Reelin+ double-positive cells, including H

243 atal subregions, with additional deficits in somatostatin-related signalling through SSTR2, may contr

244 anism mediated by stimulation of intra-islet somatostatin release.

245 genetic ablation of insulin receptors in the somatostatin-secreting delta-cells, when insulin-induced

246 We found basal glucagon, insulin and somatostatin secretion and respiration from human islets

247 ced mitochondrial metabolism but not lowered somatostatin secretion are crucial in this effect.

248 ctions, and the consequential stimulation of somatostatin secretion inhibits alpha-cell electrical ac

249 -secreting delta-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (a

250 e mainly those that express the neuropeptide somatostatin, send projections to the globus pallidus ex

251 islet cells expressing insulin, glucagon, or somatostatin share a lack of methylation at the promoter

252 gies to alter mTORC1 function selectively in somatostatin (SOM) inhibitory interneurons (SOM-INs).

253 ing animals, we show that dendrite-targeting somatostatin (SOM) interneurons are critical for a visua

254 Excitatory synapses onto somatostatin (SOM) interneurons show robust short-term f

255 associated with activation of CeL-expressing somatostatin (SOM) neurons.

256 d neuropeptides, including parvalbumin (PV), somatostatin (SOM), calretinin (CR), and cholecystokinin

257 eurons expressing either parvalbumin (PV) or somatostatin (SOM), two markers of particular sub-classe

258 However, targeting of somatostatin (SOM)- and vasoactive intestinal peptide (V

259 tive intestinal peptide (VIP)-expressing and somatostatin (SOM)-expressing inhibitory neurons modulat

260 olecystokinin (CCK+), parvalbumin (PV+), and somatostatin (SOM+) expressing interneurons are prominen

261 ers by targeting either parvalbumin (PV+) or somatostatin (SOM+) interneurons.

262 (TFs) have compensatory roles in repressing somatostatin (SST(+)) interneuron (IN) production in med

263 terations of GABAergic interneurons, notably somatostatin (Sst) as well as parvalbumin (Pvalb), in co

264 pecific activity of medial prefrontal cortex somatostatin (SST) interneurons and that activation of t

265 Here we show that activation of cortical somatostatin (SST) interneurons by Lypd6, an endogenous

266 tivity is shaped by the parvalbumin (PV) and somatostatin (SST) interneurons that inhibit principal e

267 mice and photoactivated parvalbumin (PV) and somatostatin (SST) interneurons to map the timing and st

268 ene is deleted in either parvalbumin (PV) or somatostatin (SST) interneurons, and examined their ASD-

269 files of the inhibitory parvalbumin (PV) and somatostatin (SST) interneurons.

270 A subset of cortical somatostatin (SST) neurons, the Martinotti cells, gate t

271 interneurons, as well as subtypes expressing somatostatin (Sst) or parvalbumin (Pvalb), but not gluta

272 -cAMP or 3-isobutyl-1-methylxanthine and the somatostatin (SST) receptor 2-5 antagonist H6056.

273 Radiolabeled somatostatin (sst) receptor agonists are integral to the

274 linical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better t

275 Medial ganglionic eminence (MGE)-derived somatostatin (SST)+ and parvalbumin (PV)+ cortical inter

276 brain-derived neurotrophic factor (BDNF) and somatostatin (SST), a marker of inhibitory gamma-aminobu

277 reduction of CINs expressing parvalbumin and somatostatin (Sst), and an increased number of MGE-deriv

278 ressing vasoactive intestinal peptide (Vip), somatostatin (Sst), and parvalbumin (Pvalb).

279 nd interneurons expressing parvalbumin (PV), somatostatin (SST), and vasoactive intestinal peptide (V

280 Genes encoding islet hormones [somatostatin (SST), insulin (INS), Glucagon (GCG)], diff

281 such interneuron type is the low-threshold, somatostatin (SST)-expressing cell, which is one of the

282 rgic interneurons include the low-threshold, somatostatin (SST)-expressing cells and the fast-spiking

283 igh levels of Wnt signaling and give rise to somatostatin (SST)-expressing cortical interneurons.

284 ibutions towards strong network-coupling; in Somatostatin (SST)-expressing INs, however, two physiolo

285 Concomitantly, the activity of somatostatin (SST)-expressing interneurons increased and

286 cal inhibitory inputs, particularly those of somatostatin (SST)-expressing interneurons.

287 riods of heightened arousal directly excites somatostatin (SST)-expressing interneurons.

288 e have identified three distinct subtypes of somatostatin (Sst)-expressing neurons in the mouse VTA.

289 tered by the loss of Nf1, without changes in somatostatin (SST)-positive CINs.

290 ibition in layer 1 in vivo, between axons of somatostatin (SST)-positive interneurons and apical tuft

291 of dopamine (tyrosine hydroxylase, TH+) and somatostatin (SST+) neurons in the paraventricular nucle

292 rneurons expressing parvalbumin (PV-INs) and somatostatin (SST-INs) exhibit impaired excitability in

293 hibitory interneurons, parvalbumin- (PV) and somatostatin-(SST) positive interneurons control sound-e

294 These data reveal that the somatostatin subclass of inhibitory interneurons are dri

295 tion of living HeLa cells overexpressing the somatostatin subtype-2 receptor.

296 lpha(+) inhibitory neurons of parvalbumin or somatostatin subtypes.

297 Approximately 55%, 35% and 63% of somatostatin, thyrotropin-releasing hormone (TRH) and co

298 o gain insight into the contribution of each somatostatin to specific nervous systems circuits and be

299 piny dendrites, and do not typically express somatostatin, VIP, or the muscarinic acetylcholine recep

300 Somatostatin was not detected in principal neurons but d